Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

US11872249B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Barbara Brannetti · Basel, CH
• Jennifer Brogdon · Cambridge, US
• Boris Engels · Arlington, US
• Brian Granda · Cambridge, US
• Lu Huang · Riverdale, US
• Ming Lei · Princeton, US
• Na Li · Beijing, CN
• Jimin Zhang · San Jose, US
• Carla Guimaraes · Boston, US
• Saar Gill · Philadelphia, US
• Marco Ruella · Ardmore, US
• Regina M. Young · Bryn Mawr, US

Key dates

• Filing date: Apr 30, 2021
• Grant date: Jan 16, 2024
• Expiry date: Nov 5, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.